Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S.

Haematologica. 2018 Nov;103(11):1908-1914. doi: 10.3324/haematol.2018.197194. Epub 2018 Jul 19.

2.

PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Menguy S, Prochazkova-Carlotti M, Beylot-Barry M, Saltel F, Vergier B, Merlio JP, Pham-Ledard A.

Am J Surg Pathol. 2018 Mar;42(3):326-334. doi: 10.1097/PAS.0000000000000983.

PMID:
29112015
3.

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.

Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK.

Lancet Haematol. 2015 Oct;2(10):e445-55. doi: 10.1016/S2352-3026(15)00150-7. Epub 2015 Oct 1.

PMID:
26686046
4.

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.

Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK.

Blood. 2018 Apr 19;131(16):1809-1819. doi: 10.1182/blood-2017-07-796342. Epub 2018 Feb 15.

5.

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.

Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, Qu B, Zhao Y, Wang L, Zhao WL.

Mol Cancer. 2019 Mar 30;18(1):54. doi: 10.1186/s12943-019-0977-3.

6.

CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.

Shi Y, Deng L, Song Y, Lin D, Lai Y, Zhou L, Yang L, Li X.

Int J Hematol. 2018 Sep;108(3):254-266. doi: 10.1007/s12185-018-2466-7. Epub 2018 May 10.

PMID:
29748856
7.

Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.

Nam SJ, Kim YH, Park JE, Ra YS, Khang SK, Cho YH, Kim JH, Sung CO.

Cancer Immunol Immunother. 2019 Feb;68(2):305-318. doi: 10.1007/s00262-018-2278-x. Epub 2018 Nov 27.

PMID:
30483834
8.

Prognostic impact of the tumor immune microenvironment in synovial sarcoma.

Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T, Sasaki T, Yamagishi T, Umezu H, Endo N.

Cancer Sci. 2018 Oct;109(10):3043-3054. doi: 10.1111/cas.13769. Epub 2018 Sep 16.

9.

An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.

McLemore LE, Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, Fineberg S.

Appl Immunohistochem Mol Morphol. 2018 Oct;26(9):611-619. doi: 10.1097/PAI.0000000000000485.

PMID:
28422766
10.

LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.

Burugu S, Gao D, Leung S, Chia SK, Nielsen TO.

Ann Oncol. 2017 Dec 1;28(12):2977-2984. doi: 10.1093/annonc/mdx557.

PMID:
29045526
11.

Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.

Mitteldorf C, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W.

Am J Surg Pathol. 2017 Jul;41(7):998-1004. doi: 10.1097/PAS.0000000000000851.

12.

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, Kim YA, Kim TM, Heo DS, Kim CW, Jeon YK.

Histopathology. 2016 Jun;68(7):1079-89. doi: 10.1111/his.12882. Epub 2015 Dec 1.

PMID:
26426431
13.

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

Webb JR, Milne K, Kroeger DR, Nelson BH.

Gynecol Oncol. 2016 May;141(2):293-302. doi: 10.1016/j.ygyno.2016.03.008. Epub 2016 Mar 16.

PMID:
26972336
14.

Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.

Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y.

Cancer Sci. 2017 Jan;108(1):81-90. doi: 10.1111/cas.13114. Epub 2017 Jan 21.

15.

The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.

Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.

Neuropathology. 2018 Apr;38(2):125-134. doi: 10.1111/neup.12435. Epub 2017 Oct 24.

PMID:
29067721
16.

Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.

Wang B, Pan W, Yang M, Yang W, He W, Chen X, Bi J, Jiang N, Huang J, Lin T.

Cancer Sci. 2019 Feb;110(2):489-498. doi: 10.1111/cas.13887. Epub 2018 Dec 12.

17.

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.

Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M.

Lung Cancer. 2016 Aug;98:51-58. doi: 10.1016/j.lungcan.2016.05.013. Epub 2016 May 21.

18.

Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.

Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M, Wang J, Ye X, Jin T, Zhang Z, Zhang Q.

Oncotarget. 2017 Jan 17;8(3):5414-5425. doi: 10.18632/oncotarget.14289.

19.

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.

Song MK, Park BB, Uhm J.

Int J Mol Sci. 2019 Mar 15;20(6). pii: E1326. doi: 10.3390/ijms20061326. Review.

20.

Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.

Chovanec M, Cierna Z, Miskovska V, Machalekova K, Svetlovska D, Kalavska K, Rejlekova K, Spanik S, Kajo K, Babal P, Mardiak J, Mego M.

Oncotarget. 2017 Mar 28;8(13):21794-21805. doi: 10.18632/oncotarget.15585.

Supplemental Content

Support Center